Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks

Journal of Medicinal Chemistry

Volumn 56, Issue 2, 2013, Pages 460-470

  Yin, Lina ^a,b   Hu, Qingzhong ^a   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ElexoPharm GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 (1 PYRIDIN 3 YLETHYL) 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 (1 PYRIDIN 3 YLVINYL) 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 (2 METHYL 1 PYRIDIN 4 YL PROPYL) 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 (PYRIDIN 4 YLMETHYL) 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(2 METHOXYPHENYL)(PYRIDIN 3 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(2 METHOXYPHENYL)(PYRIDIN 4 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(3 CHLOROPHENYL)(PYRIDIN 4 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(3 FLUOROPHENYL)(PYRIDIN 4 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(3 METHOXYPHENYL)(PYRIDIN 4 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(3 METHYLPHENYL)(PYRIDIN 3 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(3 METHYLPHENYL)(PYRIDIN 4 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(4 CHLOROPHENYL)(PYRIDIN 4 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(4 FLUOROPHENYL)(PYRIDIN 3 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [(4 METHOXYPHENYL)(PYRIDIN 4 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [[(3,5 BIS(TRIFLUOROMETHYL)PHENYL](PYRIDIN 4 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [CYCLOHEXYL(PYRIDIN 3 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [PHENYL(PYRIDIN 3 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; 8 [PHENYL(PYRIDIN 4 YL)METHYL] 1,2,5,6 TETRAHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 4 ONE; ALDOSTERONE SYNTHASE; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450 INHIBITOR; FADROZOLE; LETROZOLE; OXYGENASE INHIBITOR; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CARDIOVASCULAR RISK; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; NONHUMAN;

ALDOSTERONE SYNTHASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; QUINOLONES; RISK FACTORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84872777577     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301408t     Document Type: Article

References (61)

1. Miller, W. R. Endocrine treatment for breast cancers: Biological rationale and current progress J. Steroid Biochem. Mol. Biol. 1990, 37, 467-480
2. Wang, T.; You, Q.; Huang, F. S.; Xiang, H. Recent advances in selective estrogen receptor modulators for breast cancer Mini-Rev. Med. Chem. 2009, 9, 1191-1201
3. American Heart Association. Heart disease and stroke statistics: 2004 update; American Heart Association: Dallas, TX, 2003.
4. Witteman, J. C.; Grobbee, D. E.; Kok, F. J.; Hofman, A.; Valkenburg, H. A. Increased risk of atherosclerosis in women after the menopause Br. Med. J. 1989, 298, 642-644
5. Booth, E. A.; Marchesi, M.; Kilbourne, E. J.; Lucchesi, B. R. 17β-Estradiol as a receptor-mediated cardioprotective agent J. Pharmacol. Exp. Ther. 2003, 307, 395-401
6. Arias-Loza, P. A.; Muehlfelder, M.; Elmore, S. A.; Maronpot, R.; Hu, K.; Blode, H.; Hegele-Hartung, C.; Fritzemeier, K. H.; Ertl, G.; Pelzer, T. Differential effects of 17β-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease Toxicol. Pathol. 2009, 37, 969-982
7. Beer, S.; Reincke, M.; Kral, M.; Callies, F.; Ströer, H.; Dienesch, C.; Steinhauer, S.; Ertl, G.; Allolio, B.; Neubauer, S. High-dose 17β-estradiol treatment prevents development of heart failure post-myocardial infarction in the rat Basic Res. Cardiol. 2007, 102, 9-18
8. Gardner, J. D.; Murray, D. B.; Voloshenyuk, T. G.; Brower, G. L.; Bradley, J. M.; Janicki, J. S. Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts Am. J. Physiol.: Heart Circ. Physiol. 2010, 298, H497-H504
9. Jurgen, G.; Ben, H.; Gun, A.; Mitch, D.; Per Eystein, L. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J. Clin. Oncol. 2002, 20, 751-757
10. Fischer, M.; Baessler, A.; Schunkert, H. Renin angiotensin system and gender differences in the cardiovascular system Cardiovasc. Res. 2002, 53, 672-677
11. Roesch, D. M.; Tian, Y.; Zheng, W.; Shi, M.; Verbalis, J. G.; Sandberg, K. Estradiol attenuates angiotensin-induced aldosterone secretion in ovariectomized rats Endocrinology 2000, 141, 4629-4636
12. Chappell, M. C.; Gallagher, P. E.; Averill, D. B.; Ferrario, C. M.; Brosnihan, K. B. Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2.Lewis rat Hypertension 2003, 42, 781-786
13. Duprez, D. A. Aldosterone and the vasculature: Mechanisms mediating resistant hypertension J. Clin. Hypertens. 2007, 9, 13-18
14. Romagni, P.; Rossi, F.; Guerrini, L.; Quirini, C.; Santiemma, V. Aldosterone induces contraction of the resistance arteries in man Atherosclerosis 2003, 166, 345-349
15. Fejes-Tóth, G.; Náray-Fejes-Tóth, A. Early aldosterone-regulated genes in cardiomyocytes: Clues to cardiac remodeling? Endocrinology 2007, 148, 1502-1510
16. Joffe, H. V.; Adler, G. K. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation Heart Failure Rev. 2005, 10, 31-37
17. Fiebeler, A.; Luft, F. C. The mineralocorticoid receptor and oxidative stress Heart Failure Rev. 2005, 10, 47-52
18. Leibovitz, E.; Ebrahimian, T.; Paradis, P.; Schiffrin, E. L. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction J. Hypertens. 2009, 27, 2192-2200
19. Weber, K. T.; Brilla, C. G.; Campbell, S. E.; Guarda, E.; Zhou, G.; Sriram, K. Myocardial fibrosis: Role of angiotensin II and aldosterone Basic Res. Cardiol. 1993, 88, 107-124
20. Qin, W.; Rudolph, A. E.; Bond, B. R.; Rocha, R.; Blomme, E. A. G.; Goellner, J. J.; Funder, J. W.; McMahon, E. G. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure Circ. Res. 2003, 93, 69-76
21. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
22. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
23. Morphy, R. Selectively nonselective kinase inhibition: Striking the right balance J. Med. Chem. 2010, 53, 1413-1437
24. Hartmann, R. W.; Bayer, H.; Grün, G. Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins J. Med. Chem. 1994, 37, 1275-1281
25. Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme J. Med. Chem. 2006, 49, 4777-4780
26. Abadi, A. H.; Abou-Seri, S. M.; Hu, Q.; Negri, M.; Hartmann, R. W. Synthesis and biological evaluation of imidazolylmethylacridones as cytochrome P-450 enzymes inhibitors Med. Chem. Commun. 2012, 3, 663-666
27. Le Borgne, M.; Marchand, P.; Duflos, M.; Delevoye-Seiller, B.; Piessard-Robert, S.; Le Baut, G.; Hartmann, R. W.; Palzer, M. Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1H-indoles and 3-(1-azoly1-1- phenylmethyl)-1H-indoles as inhibitors of P450 arom Arch. Pharm. (Weinheim, Ger.) 1997, 330, 141-145
28. Woo, L. W. L.; Jackson, T.; Putey, A.; Cozier, G.; Leonard, P.; Acharya, K. R.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template J. Med. Chem. 2010, 53, 2155-2170
29. Leze, M. P.; Le Borgne, M.; Pinson, P.; Palusczak, A.; Duflos, M.; Le Baut, G.; Hartmann, R. W. Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 1134-1137
30. Gobbi, S.; Cavalli, A.; Negri, M.; Schewe, K. E.; Belluti, F.; Piazzi, L.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Imidazolylmethylbenzophenones as highly potent aromatase inhibitors J. Med. Chem. 2007, 50, 3420-3422
31. Al-Soud, Y. A.; Heydel, M.; Hartmann, R. W. Design and synthesis of 1,3,5-trisubstituted 1,2,4-triazoles as CYP enzyme inhibitors Tetrahedron Lett. 2011, 52, 6372-6375
32. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R. W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors J. Med. Chem. 2004, 47, 6792-6803
33. Stefanachi, A.; Favia, A. D.; Nicolotti, O.; Leonetti, F.; Pisani, L.; Catto, M.; Zimmer, C.; Hartmann, R. W.; Carotti, A. Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase J. Med. Chem. 2011, 54, 1613-1625
34. Hu, Q.; Negri, M.; Jahn-Hoffmann, K.; Zhuang, Y.; Olgen, S.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17)-Part II: Core rigidification and influence of substituents at the methylene bridge Bioorg. Med. Chem. 2008, 16, 7715-7727
35. Hille, U. E.; Hu, Q.; Vock, C.; Negri, M.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Novel CYP17 inhibitors: Synthesis, biological evaluation, structure-activity relationships and modeling of methoxy-and hydroxy-substituted methyleneimidazolyl biphenyls Eur. J. Med. Chem. 2009, 44, 2765-2775
36. Hu, Q.; Negri, M.; Olgen, S.; Hartmann, R. W. The role of fluorine substitution in biphenyl methylene imidazole type CYP17 inhibitors for the treatment of prostate carcinoma ChemMedChem 2010, 5, 899-910
37. Hu, Q.; Jagusch, C.; Hille, U. E.; Haupenthal, J.; Hartmann, R. W. Replacement of imidazolyl by pyridyl in biphenyl methylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer J. Med. Chem. 2010, 53, 5749-5758
38. Hu, Q.; Yin, L.; Jagusch, C.; Hille, U. E.; Hartmann, R. W. Isopropylidene substitution increases activity and selectivity of biphenyl methylene 4-pyridine type CYP17 inhibitors J. Med. Chem. 2010, 53, 5049-5053
39. Pinto-Bazurco Mendieta, M. A. E.; Negri, M.; Hu, Q.; Hille, U. E.; Jagusch, C.; Jahn-Hoffmann, K.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Hartmann, R. W. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modeling Arch. Pharm. (Weinheim, Ger.) 2008, 341, 597-609
40. Hille, U. E.; Hu, Q.; Pinto-Bazurco Mendieta, M. A. E.; Bartels, M.; Vock, C. A.; Lauterbach, T.; Hartmann, R. W. Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: Combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile C. R. Chim. 2009, 12, 1117-1126
41. Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-Bazurco Mendieta, M. A. E.; Rodenwaldt, B.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation and molecular modeling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17)-Part I: heterocyclic modifications of the core structure Bioorg. Med. Chem. 2008, 16, 1992-2010
42. Krug, S. J.; Hu, Q.; Hartmann, R. W. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition J. Steroid Biochem. Mol. Biol. 2013, 134, 75-79
43. Hille, U. E.; Zimmer, C.; Vock, C. A.; Hartmann, R. W. Discovery of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases ACS Med. Chem. Lett. 2011, 2, 2-6
44. Hille, U. E.; Zimmer, C.; Haupenthal, J.; Hartmann, R. W. Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases ACS Med. Chem. Lett 2011, 2, 559-564
45. Zolle, I. M.; Berger, M. L.; Hammerschmidt, F.; Hahner, S.; Schirbel, A.; Peric-Simov, B. New selective inhibitors of steroid 11β-hydroxylation in the adrenal cortex: Synthesis and structure-activity relationship of potent etomidate analogues J. Med. Chem. 2008, 51, 2244-2253
46. Yin, L.; Lucas, S.; Maurer, F.; Kazmaier, U.; Hu, Q.; Hartmann, R. W. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij ]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome J. Med. Chem. 2012, 55, 6629-6633
47. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: Lead optimization providing a series of pyridine substituted 3,4-dihydro-1 H -quinolin-2-one derivatives J. Med. Chem. 2008, 51, 8077-8087
48. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach J. Med. Chem. 2008, 51, 6138-6149
49. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity J. Med. Chem. 2008, 51, 5064-5074
50. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Marchais-Oberwinkler, S.; Hartmann, R. W. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis J. Med. Chem. 2006, 49, 2222-2231
51. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Barassin, C.; Marchais-Oberwinkler, S.; Hartmann, R. W. Heteroaryl-substituted naphthalenes and structurally modified derivatives: Selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis J. Med. Chem. 2005, 48, 6632-6642
52. Ulmschneider, S.; Müller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W. Synthesis and evaluation of (pyridylmethylene) tetrahydronaphthalenes/-indanes and structurally modified derivatives: Potent and selective inhibitors of aldosterone synthase J. Med. Chem. 2005, 48, 1563-1575
53. Ulmschneider, S.; Müller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Oberwinkler-Marchais, S.; Klein, C. D.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylene tetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase J. Med. Chem. 2005, 48, 1796-1805
54. Lucas, S.; Negri, M.; Heim, R.; Zimmer, C.; Hartmann, R. W. Fine-tuning the selectivity of aldosterone synthase inhibitors: Insights from studies from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij ]quinoline-4-one derivatives J. Med. Chem. 2011, 54, 2307-2319
55. Yin, L.; Hu, Q.; Hartmann, R. W. 3-Pyridinyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2 PLoS ONE 2012, 7 (11 e48048 10.1371/journal.pone.0048048
56. Hu, Q.; Yin, L.; Hartmann, R. W. Selective dual inhibitors of CYP19 and CYP11B2: Targeting cardiovascular diseases hiding in the shadow of breast cancer J. Med. Chem. 2012, 55, 7080-7089
57. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones J. Med. Chem. 1986, 29, 1362-1369
58. Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 chinese hamster cells Endocr. Res. 1995, 21, 443-448
59. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): Screening in fission yeast and evaluation of selectivity in V79 cells J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179
60. Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17α-hydroxylase-C(17,20)- lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63
61. Hutschenreuter, T. U.; Ehmer, P. E.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 Inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32